An interventional study of Antibiotics and Autologous Fecal Microbiota Transplantation in Physical Abilities and FMT, sponsored by Assaf-Harofeh Medical Center. Recruiting at 1 site in Israel. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Assaf-Harofeh Medical Center · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The intestinal microbiome is a microbial system that is influenced by host genetics and environmental exposures such as nutrition, stress and medications. There is a growing body of evidence indicating the significant contribution of the gut microbiome to host health and disease. Furthermore, it has been shown that exercise may modify the microbiome composition. However, important mechanistic questions related to the possible associations between exercise and the human gut microbiome remain unanswered.
In this study, the investigators are using advanced state-of-the-art measurements of physical activity level and related metabolic parameters whether there is a connection between the microbiome and physical abilities in healthy participants and whether antibiotics consumption can influence host physical abilities and glycemic responses through changes induced in microbiome composition and function.
In this interventional study participants will be followed by researchers for up to 1 month. During all days of the study participants will be connected to a continuous glucose monitor (CGM). During the study, participants will collect stool and buccal samples which will be used for microbiota profiling. Participants will receive kits in advance to collect the stool, and oral sample at home. Additionally, participants will receive a Smartwatch to track their physical activity performance.
In the second segment of the study, participants will be randomized into two groups: antibiotics or placebo, which will be consumed for 7 days.
The third segment of the trial, Participants will be allocated into three groups, to receive either 15 Autologous fecal microbiota transplantation (aFMT) capsules or 15 identical placebo capsules (participants who received antibiotics will be divided into 2 groups to receive fecal microbiota transplantation (FMT) or placebo, and participants who received placebo will receive placebo in this segment as well). The FMT will take place for two consecutive days (a total of 30 capsules).
On the fourth meeting After all tests are done, participants who received antibiotic and haven't received aFMT will undergo an FMT administration (on meetings 4-5). The FMT will take place on two consecutive days (a total of 30 capsules) in the same manner it was described above. The other 2 groups will receive a placebo capsules as described above.
Participants will undergo physical abilities tests (VO2max test, muscle strength will be valued with "System 4 Pro™ BIODEX " or a manual dynamometer, high jumps, 30 seconds jumps, flexibility. Before, immediately after, and following 1,3, 5, 7 and 9 minutes of the 30 seconds jumps, finger prick blood samples will be taken for lactate measurement), anthropometric measurements, medical history questioners, blood samples and body composition using DXA.
All adverse events will be documented and reported as necessary to the study doctor and the ethical committee.
An additional cohort of 18 days (group b) will be recruited in order to examine the role of the gut microbiome in contributing to exercise capacity, particularly through D-lactate generation.
Participants will be asked to perform cycles of 4-minute efforts, increasing capacity by 10-15% per stage. Blood lactate at the end of each stage will be collected. Cycles will stop once the participant reached their lactate threshold, monitered by the finger prick lactate measurement and or if the participant cannot sustain the workload. Similarly to the first cohort, participants will be randomized to receive either antibiotics or placebo. Participants in the antibiotics arm will receive their aFMT to restore their pre-antibiotic gut microbiome, by ingesting 30 pills of FMT, and the placebo group will receive 30 pills of Cellulose.
Assaf-Harofeh Medical Center is the lead sponsor of 267 studies on the registry; 43 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 13, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
7 days of antibiotics- Ciprofloxacin, 500 mg 2/day \& Metronidazole (Flagyl), 500 mg 3/day. After antibiotics administration, participants will receive 15 aFMT capsules for two consecutive days (a total of 30 capsules). On the forth + fifth meeting, participants who received antibiotic FMT will receive a 30 placebo capsules
Drug: Antibiotics · Other: Autologous Fecal Microbiota Transplantation · Other: placebo capsules
7 days of placebo cellulose pills. After cellulose pills administration, participants will receive 15 placebo capsules for two consecutive days (a total of 30 capsules). On the forth + fifth meeting, the participants will again receive 30 placebo capsules.
Other: Cellules Pills · Other: placebo capsules
7 days of antibiotics- Ciprofloxacin, 500 mg 2/day \& Metronidazole (Flagyl), 500 mg 3/day. After antibiotics administration participants will receive 15 placebo capsules. On the forth + fifth meeting the participants will receive 15 aFMT capsules for two consecutive days (a total of 30 capsules).
Drug: Antibiotics · Other: Autologous Fecal Microbiota Transplantation · Other: placebo capsules
Ciprofloxacin, 500 mg 2/day \& Metronidazole (Flagyl), 500 mg 3/day.
Also known as: Ciprofloxacin & Metronidazole
Autologous Fecal Microbiota Transplantation( aFMT( stool taken from the participant, prior to antibiotic treatment)
Also known as: FMT
7 days of cellules placebo pills.
Placebo capsules consist of saline/glycerol (the same vehicle as in a FMT capsules)
Microbiome Profiling
Using stool and buccal samples for microbiome composition analysis
Time frame: 1 month
Physical ability
will be measured by several tests: flexibility, Biodex, maximal oxygen uptake (VO2 max), high jumps, 30 seconds jumps, lactate measurement.
Time frame: 1 month
Glycemic Responses
Performing continuous glucose monitor (CGM)
Time frame: 1 month
D- lactate measurement
measuring D-Lactate threshold
Time frame: 18 days
Plan to share: No
Started Jun 2022 (actual). Primary completion is estimated for Dec 2028, 78 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: start Jan 2022 → Jun 2022, primary completion Jul 2022 → Dec 2028 and completion Jan 2023 → Dec 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assaf-Harofeh Medical Center →